LG Chem helps the people to lead a healthy life by strengthening its R&D competence in Life Sciences.
Life Sciences is the company's new growth engine in the mid to long term goal. The company has secured the differentiated R&D competence and has received the U.S. FDA approval for its new drugs for the first time in Korea.
The company has actively penetrated into the overseas market and has expanded the pipelines for developing new drugs with active investment in R&D. The company is doing its best to become one of the best global pharmaceutical companies.
Sales
0.53KRW trillion
2016
0.55KRW trillion
2017
0.57KRW trillion
2018
  • 1984 Established Pharmaceuticals business division
  • 1991 Developed World’s first4th generation Cephalosporin
  • 2003 1st Korean NCE approved by USA FDA(Factive)
  • 2017 Merged with LG Life Sciences
Division
Primary Care (PC) Primary Care (PC)
Special Care(SC) Special Care(SC)
Aesthetic Aesthetic
Pipeline (New Drug)
Pipeline (New Drug) : Disease area , Code, Indication, Development stage, Research , Preclinical , clinical, Phase I , Phase II , Phase III , Remark
Disease area Code Indication Development stage Remark
Research Preclinical Phase I Phase II Phase III
Metabolic disease
LR19052
Diabetes
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Zemiglo® combination drug (Korea)
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
LR19054
Diabetes
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
Zemiglo® combination drug (China)
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
LR19051
Diabetes
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
Zemiglo® combination drug (Thailand)
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
LR19123
Diabetes
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19018
Diabetes
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19074
Gout
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
LR19021
Obesity
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19020
Obesity
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19131
Metabolic disease
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Oncology
LR19127
Oncology
Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Co-developed with Cue Biopharma
Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19125
Oncology
Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Co-developed with PDC Line
Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19129
Oncology
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Co-developed with Cue Biopharma
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19031
Oncology
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19023
Oncology
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Immunology
LR19055
Autoimmune disease
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Humira biosimilar
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
LR19019
Autoimmune disease
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding
LR19025
Degenerative disease
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19024
Degenerative disease
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
LR19030
Alopecia
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding
Medical Device and Vaccine
Pipeline (New Drug) : Disease area , Code, Indication, Development stage, Research , Preclinical , clinical, Phase I , Phase II , Phase III , Remark
Disease area Code Indication Development stage Remark
Research Preclinical Phase I Phase II Phase III
Medical Device
LR19059
Dermal filler
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
China
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
LR19059
Dermal filler
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Europe
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Vaccine
LR19113
Polio
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
pneumococcus
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
LR19122
diphtheriae, tetanus, pertussis, hepatitis B, meningitis, polio
Research complete Preclinical complete Phase I complete Phase II Before proceeding Phase III Before proceeding
pneumococcus
Research complete Preclinical complete Phase I complete Phase II Before proceeding Phase III Before proceeding
LR19115
Funded by BMGF
Research complete Preclinical complete Phase I complete Phase II Proceeding Phase III Before proceeding
Research complete Preclinical complete Phase I complete Phase II Proceeding Phase III Before proceeding
Core Products
Eutropin Eutropin
Hyruan One Hyruan One
Zemiglo Zemimet SR Tab Zemiglo / Zemimet SR Tab
Eucept Eucept
YVOIRE YVOIRE